COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome

Matthieu Dietz, Gilles Chironi, Yann-Erick Claessens, Ryan Lukas Farhad, Isabelle Rouquette, Benjamin Serrano, Valérie Nataf, Florent Hugonnet, Benoît Paulmier, Frédéric Berthier, Olivia Keita-Perse, Francesco Giammarile, Christophe Perrin, Marc Faraggi, MONACOVID Group, C Fissore-Magdelein, S Gabriel-Solean, B Dahmani, I Riss, P Sorlin, V Dupasquier, A Pathak, C Dugourd, M Nicolai, N Rijo, N Beau, X Magdelein, F Olyve, S Chaillou-Orpitz, J Lépine, M Lorillou, C Maincent, S Bertrand, P Brunner, C Dittlot, F Fuerxer, M Liberatore, G Armando, M Bouregba, J Catineau, P Garcia, D Tran, Matthieu Dietz, Gilles Chironi, Yann-Erick Claessens, Ryan Lukas Farhad, Isabelle Rouquette, Benjamin Serrano, Valérie Nataf, Florent Hugonnet, Benoît Paulmier, Frédéric Berthier, Olivia Keita-Perse, Francesco Giammarile, Christophe Perrin, Marc Faraggi, MONACOVID Group, C Fissore-Magdelein, S Gabriel-Solean, B Dahmani, I Riss, P Sorlin, V Dupasquier, A Pathak, C Dugourd, M Nicolai, N Rijo, N Beau, X Magdelein, F Olyve, S Chaillou-Orpitz, J Lépine, M Lorillou, C Maincent, S Bertrand, P Brunner, C Dittlot, F Fuerxer, M Liberatore, G Armando, M Bouregba, J Catineau, P Garcia, D Tran

Abstract

Purpose: [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19.

Methods: Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients' profiles were classified as "inflammatory" or "low inflammatory." FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism.

Results: Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome.

Conclusion: Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs.

Trial registration: NCT04441489. Registered 22 June 2020 (retrospectively registered).

Keywords: COVID-19; FDG PET/CT; Inflammation.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Study flow chart. Twenty-six patients with laboratory-confirmed COVID-19 were hospitalized at the Centre Hospitalier Princesse Grace of Monaco from March 27th to May 3rd, 2020. Twelve patients were excluded because they were admitted out of the selected time period from the onset of the symptoms or without chest CT ground-glass opacities or consolidation. One patient was secondary excluded because further elicitation retrospectively revealed the onset of symptoms occurred 22 days before FDG PET/CT study
Fig. 2
Fig. 2
A 53-year-old man patient with moderate respiratory symptoms referred for FDG PET/CT at day 14 after the onset of symptoms. Images showed multiple peripheral and bilateral ground-glass opacities with intense increased FDG uptake (SUVmax 16.3). The following day, respiratory status dramatically improved without need of supplemental oxygen, and patient was discharged from hospital 3 days later. Left: A CT transverse slice, B FDG PET slice, and C FDG PET and CT-fused images. Right: whole-body maximal intensity projection (MIP) image, displaying also mediastinal lymph nodes FDG uptake
Fig. 3
Fig. 3
A 55-year-old man patient who presented severe respiratory symptoms in the days before FDG PET/CT. Images showed bilateral consolidation with mild increased FDG uptake (SUVmax 5). Despite this mild inflammation, the patient remained symptomatic for days requiring oxygen therapy through nasal canula at low flow rates and was discharged from hospital only 13 days later. Left: A CT transverse slice, B FDG PET slice, and C FDG PET and CT-fused images. Right: whole-body MIP image demonstrating that FDG uptake in mediastinal lymph nodes is above lung FDG uptake (respectively, SUVmax 6.9 versus 5)

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.
    1. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020. 10.1164/rccm.202003-0543OC.
    1. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, Xie G, Lin S, Wang R, Yang X, Chen W, Wang Q, Zhang D, Liu Y, Gong R, Ma Z, Lu S, Xiao Y, Gu Y, Zhang J, Yao H, Xu K, Lu X, Wei G, Zhou J, Fang Q, Cai H, Qiu Y, Sheng J, Chen Y, Liang T. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020. BMJ. 2020;369:m1443. doi: 10.1136/bmj.m1443.
    1. Lee E, Ng MY, Khong PL. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis. 2020;20(4):384–385. doi: 10.1016/S1473-3099(20)30134-1.
    1. Li Y, Yao L, Li J, Chen L, Song Y, Cai Z, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020. 10.1002/jmv.25786.
    1. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020:201561. 10.1148/radiol.2020201561.
    1. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, Zhang Z, Guan W, Ling Z, Jiang R, Hu T, Ding Y, Lin L, Gan Q, Luo L, Tang X, Liu J. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47(5):1275–1280. doi: 10.1007/s00259-020-04735-9.
    1. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur J Radiol. 2020;127:109009. doi: 10.1016/j.ejrad.2020.109009.
    1. de Prost N, Tucci MR, Melo MF. Assessment of lung inflammation with 18F-FDG PET during acute lung injury. AJR Am J Roentgenol. 2010;195(2):292–300. doi: 10.2214/AJR.10.4499.
    1. Chefer S, Thomasson D, Seidel J, Reba RC, Bohannon JK, Lackemeyer MG, Bartos C, Sayre PJ, Bollinger L, Hensley LE, Jahrling PB, Johnson RF. Modeling [(18)F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndrome-coronavirus aerosol challenge. EJNMMI Res. 2015;5(1):65. doi: 10.1186/s13550-015-0143-x.
    1. Chen DL, Bedient TJ, Kozlowski J, Rosenbluth DB, Isakow W, Ferkol TW, Thomas B, Mintun MA, Schuster DP, Walter MJ. [18F] fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation. Am J Respir Crit Care Med. 2009;180(6):533–539. doi: 10.1164/rccm.200904-0501OC.
    1. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 2020. Published January 25, 2020. Accessed Mar 20, 2020.
    1. Paez D, Gnanasegaran G, Fanti S, Bomanji J, Hacker M, Sathkge M, et al. COVID-19 pandemic: guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging. 2020. 10.1007/s00259-020-04825-8.
    1. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020:200463. 10.1148/radiol.2020200463.
    1. Marjanovic S, Skog S, Heiden T, Tribukait B, Nelson BD. Expression of glycolytic isoenzymes in activated human peripheral lymphocytes: cell cycle analysis using flow cytometry. Exp Cell Res. 1991;193:425–431. doi: 10.1016/0014-4827(91)90116-C.
    1. Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, Sato N, Konishi J. Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med. 2002;43:658–663.
    1. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020:1–8.
    1. Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402. doi: 10.1016/S2213-2600(18)30064-X.
    1. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020:1–4.
    1. Setti L, Kirienko M, Dalto SC, Bonacina M, Bombardieri E. FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients. Eur J Nucl Med Mol Imaging. 2020. 10.1007/s00259-020-04819-6.
    1. Zou S, Zhu X. FDG PET/CT of COVID-19. Radiology. 2020:200770. 10.1148/radiol.2020200770.
    1. Qin C, Liu F, Yen TC, Lan X. 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging. 2020;47:1281–1286. doi: 10.1007/s00259-020-04734-w.
    1. Polverari G, Arena V, Ceci F, Pelosi E, Ianniello A, Poli E, et al. 18F-fluorodeoxyglucose uptake in patient with asymptomatic severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019) Referred to positron emission tomography/computed tomography for NSCLC restaging. J Thorac Oncol. 2020;0. 10.1016/j.jtho.2020.03.022.
    1. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi: 10.1038/nature02145.
    1. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi: 10.1002/path.1570.
    1. Ahn SS, Hwang SH, Jung SM, Lee SW, Park YB, Yun M, Song JJ. Evaluation of spleen glucose metabolism using 18F-FDG PET/CT in patients with febrile autoimmune disease. J Nucl Med. 2017;58(3):507–513. doi: 10.2967/jnumed.116.180729.
    1. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578–588. doi: 10.1161/01.CIR.99.4.578.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever